Anadis clinical trial gets go-ahead
Wednesday, 03 September, 2008
The Israeli Ministry of Health has approved Anadis' (ASX:ANX) clinical protocol, clearing the way for trials of its mucositis treatment to begin within a month.
Mucostisis is a significant side effect of cancer therapy, experienced by between 20 and 100 per cent of patients, depending on the type of cancer and treatment.
Effects include painful mouth ulcerations and severe gastrointestinal symptoms.
The Anadis drug contains a unique formulation of Anadis' immune milk-derived anti LPS antibodies as well as other bioactives, and will be delivered using Anadis' oral delivery technology.
Anadis was recently awarded a grant from Vistech to help fund the drug development program.
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
